These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23075240)

  • 1. The cancer testis antigen PRAME as a biomarker for solid tumor cancer management.
    Goodison S; Urquidi V
    Biomark Med; 2012 Oct; 6(5):629-32. PubMed ID: 23075240
    [No Abstract]   [Full Text] [Related]  

  • 2. Oncofetal signaling as a target for cancer therapy.
    Ahrlund-Richter L; Hendrix MJ
    Semin Cancer Biol; 2014 Dec; 29():1-2. PubMed ID: 25111377
    [No Abstract]   [Full Text] [Related]  

  • 3. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
    Atanackovic D; Luetkens T; Kloth B; Fuchs G; Cao Y; Hildebrandt Y; Meyer S; Bartels K; Reinhard H; Lajmi N; Hegewisch-Becker S; Schilling G; Platzbecker U; Kobbe G; Schroeder T; Bokemeyer C; Kröger N
    Am J Hematol; 2011 Nov; 86(11):918-22. PubMed ID: 21898529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
    Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
    Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer.
    Xu Y; Zou R; Wang J; Wang ZW; Zhu X
    Cell Prolif; 2020 Mar; 53(3):e12770. PubMed ID: 32022332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
    Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A
    Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers in cancer research and treatment: promises and challenges.
    Hainaut P; Plymoth A
    Curr Opin Oncol; 2011 Jan; 23(1):61. PubMed ID: 21321519
    [No Abstract]   [Full Text] [Related]  

  • 8. PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma.
    Brenne K; Nymoen DA; Reich R; Davidson B
    Am J Clin Pathol; 2012 Feb; 137(2):240-7. PubMed ID: 22261449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
    Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
    Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Desmoplastic melanoma: comparison of expression of differentiation antigens and cancer testis antigens.
    Lim E; Browning J; MacGregor D; Davis ID; Cebon JS
    Melanoma Res; 2006 Aug; 16(4):347-55. PubMed ID: 16845331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation.
    Liberante FG; Pellagatti A; Boncheva V; Bowen DT; Mills KI; Boultwood J; Guinn BA
    Br J Haematol; 2013 Jul; 162(2):282-5. PubMed ID: 23594062
    [No Abstract]   [Full Text] [Related]  

  • 12. Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia.
    Spanaki A; Perdikogianni C; Linardakis E; Kalmanti M
    Leuk Res; 2007 May; 31(5):639-42. PubMed ID: 16860864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-associated antigens and biomarkers in cancer and immune therapy.
    Malyankar UM
    Int Rev Immunol; 2007; 26(3-4):223-47. PubMed ID: 17558745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BJ-HCC-20, a potential novel cancer-testis antigen.
    Dong XY; Li YY; Yang XA; Chen WF
    Biochem Cell Biol; 2004 Oct; 82(5):577-82. PubMed ID: 15499386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA dysregulation in cancer: opportunities for the development of microRNA-based drugs.
    Nana-Sinkam SP; Croce CM
    IDrugs; 2010 Dec; 13(12):843-6. PubMed ID: 21154140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia.
    Ortmann CA; Eisele L; Nückel H; Klein-Hitpass L; Führer A; Dührsen U; Zeschnigk M
    Ann Hematol; 2008 Oct; 87(10):809-18. PubMed ID: 18587578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is everything known in all faces of iceberg in PRAME?
    Paydas S
    Leuk Res; 2008 Sep; 32(9):1356-7. PubMed ID: 18400297
    [No Abstract]   [Full Text] [Related]  

  • 18. Tapping the treasure of intracellular oncotargets with immunotherapy.
    Hong CW; Zeng Q
    FEBS Lett; 2014 Jan; 588(2):350-5. PubMed ID: 24184114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer.
    Epping MT; Bernards R
    Cancer Res; 2006 Nov; 66(22):10639-42. PubMed ID: 17108098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-testis antigens: potential targets for cancer immunotherapy.
    Ghafouri-Fard S; Modarressi MH
    Arch Iran Med; 2009 Jul; 12(4):395-404. PubMed ID: 19566358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.